Clinical trial
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Recruiting now · Phase 3 · 5 countries · Registry ID NCT07564414
What this study is about
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
Basic eligibility
Full registry criteria
Treatments and study arms
Cagrisema
Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.
Semaglutide
Semaglutide will be administered subcutaneously.
Primary outcomes
Measured as percentage (%).
Study locations
303 locations were listed when this page was built. The first 40 are shown.